



Shilpa Medicare Ltd.
Registered office # 12-6-214/A-1 Hyderabad Road Raichur
Website - www.vbshilpa.com, Email - info@vbshilpa.com, Telephone - +91-8532-238494
CIN No. - L85110KA1987PLC008739

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2016

Particulars	(Rs in Lakhs)				
	Quarter ended 31st Dec, 2016 as per Ind AS	Quarter ended 30th Sept, 2016 as per Ind AS	Quarter ended 31st Dec, 2015 as per Ind AS	For Current Nine Month ended 31st Dec 2016 as per Ind AS	For Previous Nine Month ended 31st Dec 2015 as per Ind AS
	(Unaudited)	(Unaudited)	(Unaudited) (Refer Note 03 below)	(Unaudited)	(Unaudited) (Refer Note 03 below)
1) Revenue from operations (Gross)	17,594.64	19,558.68	19,034.47	53,091.18	50,040.09
Total Income	17,594.64	19,558.68	19,034.47	53,091.18	50,040.09
Expenses					
2) a) Cost of material consumed	9,325.05	8,506.14	9,530.05	27,387.13	27,551.96
b) Purchase of stock in trade	283.74	61.29	242.19	370.59	313.31
c) Changes in inventories of finished goods, WIP, Stock in Trade	(1,023.23)	1,966.46	929.05	(131.84)	(587.50)
d) Employee benefit expense	2,248.41	2,166.52	1,885.72	6,343.81	5,011.59
e) Depreciation and amortization expenses	680.61	645.77	541.74	1,931.14	1,544.78
f) Excise duty recovered	153.30	147.38	138.56	409.27	416.33
g) Other expenses	2,482.48	1,821.92	1,999.97	6,109.67	5,742.18
Total Expenses	14,150.36	15,315.48	15,267.28	42,419.77	39,992.65
3) Profit before tax and exceptional items	3,444.28	4,243.20	3,767.19	10,671.41	10,047.44
4) Other income	328.61	377.88	212.19	957.56	795.68
5) Profit from ordinary activities before finance cost, exceptional item	3,772.89	4,621.08	3,979.38	11,628.97	10,843.12
6) Finance cost	71.92	58.76	82.62	200.20	256.46
7) Profit from ordinary activities before exceptional item & taxes	3,700.97	4,562.32	3,896.76	11,428.77	10,586.66
8) Exceptional Loss	-	-	-	-	241.96
9) Profit Before Tax and after exceptional items	3,700.97	4,562.32	3,896.76	11,428.77	10,344.70
10) Tax Expense:	966.28	1,243.35	683.53	2,966.14	2,403.58
11) Profit for the Period	2,734.69	3,318.97	3,213.23	8,462.63	7,941.12
12) Other comprehensive income					
13) Items that will not be reclassified to profit or loss					
a) Gain / (Loss) on Remeasurement of net defined benefit liability/asset	5.35	5.27	5.14	16.27	15.41
b) MTM Gain / (Loss) on financial instruments	(186.66)	-	-	(186.66)	-
14) Total Other comprehensive income, net of tax	(181.31)	5.27	5.14	(170.39)	15.41
15) Total comprehensive income for the period	2,553.38	3,324.24	3,218.37	8,292.24	7,956.53
16) Paid up Share Capital (par Value Rs.1/- each, fully paid)	801.27	771.02	771.02	801.27	771.02
17) Earnings per equity share (par value Rs.1/- each)					
Basic (Rs.)	3.31	4.31	4.17	10.74	10.32
Diluted (Rs.)	3.31	4.31	4.17	10.74	10.32

Notes:

1. Transition to Ind AS

The Company has transitioned to Ind AS with effect from 1st April 2015 and for that purpose comparative figures for the quarter & year ended 31st December 2015, has been restated and accordingly the impact of transition has been provided.

2. Reconciliation of results between previous Indian GAAP and Ind AS

Particulars	Quarter ended 31st Dec 2015	Nine Month ended 31st Dec 2015
Profit / Loss as per Indian GAAP	3,221.20	7,752.91
Add / (Less) Adjustments		
Capital Subsidy accounted using Income Approach	2.76	8.29
Recognition of MTM Gain/loss on Interest rate swaps	13.13	28.02
Investment recognised at fair value	(37.57)	215.25
Leasehold land amortisation being treated as operating lease	(4.18)	(12.25)
Impact of amortisation of fair value of corporate guarantee	8.79	23.95
Deferred tax impact on Ind AS Adjustments	5.90	(91.11)
Prior period errors	8.34	31.47
Profit / Loss as per Ind AS	3,218.37	7,956.53



3. The unaudited standalone financial results for the quarter and nine months ended 31-Dec-2016 of Shilpa Medicare Ltd (the company) have been reviewed by the Audit Committee and approved Board of Directors of the Company and that the same were also subjected to limited review by the statutory auditors of the Company. Further the Ind-AS compliant financial results for the corresponding quarter and for the nine month ended as at 31-Dec-2015 have not been subject to limited review by the statutory auditors in terms of SEBI circular dated 05-July-2016. However, the management has exercised necessary due diligence to ensure that the Quarterly unaudited financial results provide a true and fair view of the Company's affairs.

4. These unaudited financial results have been prepared in accordance with Indian Accounting Standard (Ind-AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 and SEBI Circular dated

5. The exceptional item for the nine months ended 31-December-2015 represents the loss on buy back of shares by its foreign subsidiary Makindus Pharmaceuticals Inc.

6. There is a possibility that these quarterly financial results may require additional adjustment before constituting the final Ind AS financial statements as of and for the year ending 31st March 2017 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.

7. As the Company is operating in only one segment "Pharmaceuticals Products", segment reporting is not applicable.

8. Other Expenses for the quarter ended 31.12.2016 includes CSR expenditure of Rs 185.12 lakhs incurred by the Company pertaining to previous financial year.

9. Prior period / year figures have been reclassified where ever required to conform to the classification of current period / year.

Place/Camp: Hyderabad
Date: 14.02.2017

By, The order of the Board of Director



Managing Director





Innovating for
affordable healthcare

Shilpa Medicare Ltd.

Registered office # 12-6-214/A-1 Hyderabad Road Raichur

Website - www.vbshilpa.com, Email - info@vbshilpa.com., Telephone -+91-8532-238494

CIN No. - L85110KA1987PLC008739

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST ,DECEMBER, 2016

Particulars	Quarter ended	Quarter ended	Quarter ended	For Current Nine	Quarter ended
	31st Dec, 2016 as	30th Sept, 2016 as	31 st Dec, 2015 as	month ended	31 st Dec, 2015
	per Ind AS	per Ind AS	per Ind AS	31,Dec, 2016 as	as per Ind AS
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
			(Refer Note 03 below)		(Refer Note 03 below)
					(Rs in Lakhs)
1) Revenue from operations (Gross)	18,357.73	21,127.26	20,003.79	56,173.85	52,443.53
Total Income	18,357.73	21,127.26	20,003.79	56,173.85	52,443.53
2) Expenses					
a) Cost of material consumed	9,588.43	8,642.10	9,718.31	28,017.88	28,043.79
b) Purchase of stock in trade	283.74	61.29	242.19	370.59	313.31
c) Changes in inventories of finished goods, WIP, Stock in Trade	(1,210.61)	2,099.81	993.72	(412.79)	(673.86)
d) Employee benefit expense	3,129.92	3,019.48	2,467.93	8,828.99	6,710.22
e) Depreciation and amortization expenses	776.77	745.16	586.80	2,218.10	1,685.20
f) Excise duty recovered	165.42	160.08	140.98	441.95	423.54
g) Other expenses	2,917.62	2,252.51	2,252.79	7,252.26	6,668.93
Total Expenses	15,651.29	16,980.43	16,402.73	46,716.97	43,171.13
3) Profit before tax and exceptional items	2,706.44	4,146.84	3,601.07	9,456.87	9,272.40
4) Other Income	402.90	369.31	198.68	1,009.61	765.52
5) Profit from ordinary activity before finance cost, exceptional item & taxes	3,109.33	4,516.15	3,799.75	10,466.49	10,037.92
6) Finance cost	72.57	59.44	83.88	202.53	260.42
8) Profit from ordinary activity before exceptional item & taxes	3,036.76	4,456.71	3,715.87	10,263.96	9,777.50
9) Exceptional Loss	-	-	-	-	241.86
10) Profit Before Tax and after exceptional items	3,036.76	4,456.71	3,715.87	10,263.96	9,535.64
11) Tax Expense:	964.98	1,237.15	672.95	2,997.65	2,363.12
12) Profit for the Period	2,071.78	3,219.56	3,042.92	7,266.30	7,172.52
13) Add : Share of Profit /(Loss) of joint venture	(366.98)	543.03	(333.96)	(446.50)	(499.31)
14) Add :Minority Interest (loss) / Profit	(40.08)	(61.70)	(62.76)	(188.50)	(236.96)
15) Net Profit after tax, minority interest, & share of Joint venture	1,744.88	3,824.30	2,771.72	7,008.30	6,910.17
16) Other comprehensive income					
a) Remeasurement of the net defined benefit liability/asset	5.35	5.27	5.14	16.27	15.41
b) Gain/ (Loss) on MTM Derivates instruments	(186.66)	-	-	(186.66)	-
17) Other comprehensive income, net of tax	(181.32)	5.27	5.14	(170.39)	15.41
18) Total comprehensive income for the period	1,563.56	3,829.57	2,776.86	6,837.91	6,925.58
19) Paid up Share Capital (par Value Rs.1/- each, fully paid)	801.27	771.02	771.02	801.27	771.02
20) Earnings per equity share (par value Rs.1/- each)					
Basic (Rs.)	2.03	4.97	3.60	8.86	8.98
Diluted (Rs.)	2.03	4.97	3.60	8.86	8.98



Transition to Ind AS

1) The Company has transitioned to Ind AS with effect from 1st April 2015 and for that purpose comparative figures for the quarter & year ended 31st December 2015, has been restated and accordingly the impact of transition has been provided.

2) Reconciliation of results between previous Indian GAAP and Ind AS

Particulars	Quarter ended	Nine ended
	31st Dec 2015	31st Dec 2015
Profit / Loss as per Indian GAAP	2,800.76	6,629.15
Add / (Less) Adjustments	-	-
Capital Subsidy accounted using Income Approach	3.10	9.29
Recognition of MTM Gain/(loss) on Interest rate swaps	13.13	28.02
Investment recognised at fair value	(37.57)	215.25
Leasehold land amortisation being treated as operating lease	4.18	(12.25)
Impact of amortisation of fair value of corporate guarantee	8.79	23.95
Prior Period Errors	34.13	31.48
Deferred tax impact on Ind AS Adjustments	(6.85)	(85.16)
Other	(42.81)	85.86
Profit / Loss as per Ind AS	2,776.86	6,925.58

3. The unaudited standalone financial results for the quarter and nine months ended 31-Dec-2016 of Shilpa Medicare Ltd (the company) have been reviewed by the Audit Committee and approved Board of Directors of the Company and that the same were also subjected to limited review by the statutory auditors of the Company. Further the Ind-AS compliant financial results for the corresponding quarter and for the nine month ended as at 31-Dec-2015 have not been subject to limited review by the statutory auditors in terms of SEBI circular dated 05-July-2016. However, the management has exercised necessary due diligence to ensure that the Quarterly unaudited financial results provide a true and fair view of the Company's affairs.

4. These unaudited financial results have been prepared in accordance with Indian Accounting Standard (Ind-AS) prescribed under section 133 of the Companies Act 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 and SEBI Circular dated

5. The exceptional item for the nine months ended 31-December-2015 represents the loss on buy back of shares by its foreign subsidiary Makindus Pharmaceuticals Inc.

6. There is a possibility that these quarterly financial results may require additional adjustment before constituting the final Ind AS financial statements as of and for the year ending 31st March 2017 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.

7 As the Company is operating in only one segment "Pharmaceuticals Products", segment reporting is not applicable.

8 Other Expenses for the quarter ended 31.12.2016 includes CSR expenditure of Rs 185.12 lakhs incurred by the Company pertaining to previous financial year.

9. The financial statements prepared for the period ended 30.09.2016 for Makindus Inc (Subsidiary) have been considered for the purpose of preparing consolidated financial statements for the quarter and nine months ended 31.12.2016.

10 Prior period / year figures have been reclassified where ever required to confirm to the classification of current period / year.

Place / Camp: Hyderabad

Date: 14.02.2017

By, The order of the Board of Director


Managing Director

